|Home | About | Journals | Submit | Contact Us | Français|
The adult mammalian brain and spinal cord contain glial precursors that express platelet-derived growth factor receptors (alpha subunit, PDGFRA) and the NG2 proteoglycan. These “NG2 cells” descend from oligodendrocyte precursors in the perinatal CNS and continue to generate myelinating oligodendrocytes in the grey and white matter of the postnatal brain. It has been proposed that NG2 cells can also generate reactive astrocytes at sites of CNS injury or demyelination. To test this we examined the fates of PDGFRA/ NG2 cells in the mouse spinal cord during experimental autoimmune encephalomyelitis (EAE) - a demyelinating condition that models some aspects of multiple sclerosis in humans. We administered tamoxifen to Pdgfra-CreERT2: Rosa26R-YFP mice in order to induce yellow fluorescent protein (YFP) expression in PDGFRA/ NG2 cells and their differentiated progeny. We subsequently induced EAE and observed a large (>4-fold) increase in the local density of YFP+ cells, >90% of which were oligodendrocyte lineage cells. Many of these became CC1-positive, NG2-negative differentiated oligodendrocytes that expressed myelin markers CNP and Tmem10/ Opalin. PDGFRA/ NG2 cells generated very few GFAP+ reactive astrocytes (1-2% of all YFP+ cells) or NeuN+ neurons (<0.02%). Thus, PDGFRA/ NG2 cells act predominantly as a reservoir of new oligodendrocytes in the demyelinated spinal cord.
Oligodendrocytes (OLs) synthesize central nervous system (CNS) myelin, which is required for fast saltatory transmission of action potentials. In multiple sclerosis (MS) OLs die, possibly through autoimmune attack, and demyelination results. During this and other demyelinating diseases there is spontaneous regeneration of lost OLs and myelin. The replacement OLs are believed to originate from adult oligodendrocyte precursors (OLPs), which are widespread and abundant in the adult CNS (ffrench-Constant and Raff, 1986;Wolswijk and Noble, 1989;Pringle et al., 1992;Butt et al., 2005;Wilson et al., 2006). Adult OLPs, also known as “NG2 cells”, co-express PDGFRA and the NG2 proteoglycan (Nishiyama et al., 1999;Wilson et al., 2006) and are antigenically similar to OLPs in the perinatal CNS. Perinatal OLPs generate OLs in vitro and in the early postnatal period in vivo (Raff et al., 1983;Hall et al., 1996;Zhu et al., 2008;Guo et al., 2009). They also generate a subset of protoplasmic astrocytes during perinatal development (Zhu et al., 2008;Guo et al., 2009). Adult OLPs continue to divide and generate new myelinating OLs in the healthy adult mouse CNS (Horner et al., 2000;Dawson et al., 2003;Aguirre and Gallo, 2004;Dimou et al., 2008;Rivers et al., 2008), though at a steadily decreasing rate with age (Lasiene et al., 2009;Psachoulia et al., 2009). They do not appear to generate astrocytes during normal adulthood (Dimou et al., 2008;Rivers et al., 2008). There is evidence that NG2 cells can generate small numbers of neurons during adulthood, although this remains controversial (Aguirre and Gallo, 2004;Dayer et al., 2005;Tamura et al., 2007;Rivers et al., 2008;Guo et al., 2010).
Several studies have indicated that adult NG2 cells can generate remyelinating OLs following experimental demyelination in rodents (Gensert and Goldman, 1997;Keirstead et al., 1998; Redwine and Armstrong, 1998;Watanabe et al., 2002;Polito and Reynolds, 2005;Zawadzka et al., 2010). There is also circumstantial evidence that NG2 cells generate remyelinating OLs during MS in humans (Nishiyama et al., 1999;Wilson et al., 2006). However, neither in rodents nor humans has it been demonstrated unequivocally that NG2 cells can regenerate OLs in conditions of chronic demyelination. Moreover, it is not known whether the reported multi-lineage differentiation potential of NG2 cells is realized - or augmented - in the abnormal environment of the injured CNS. To establish the differentiation fates of PDGFRA/ NG2 cells during MS-like pathology we administered tamoxifen (Tam) to adult Pdgfra-CreERT2: Rosa26R-YFP double-transgenic mice to induce YFP labelling of PDGFRA-expressing cells, then induced experimental autoimmune encephalomyelitis (EAE) by immunizing with emulsified myelin oligodendrocyte glycoprotein (MOG) peptide. This caused widespread demyelination along the neuraxis. We subsequently identified YFP-labeled PDGFRA/ NG2 cells and their differentiated progeny by immunohistochemistry. Our lineage tracing study provides direct evidence that PDGFRA/ NG2 cells generate new OLs in the demyelinated spinal cord. By comparison, PDGFRA/ NG2 cells produced very few astrocytes and practically no neurons. A significant fraction (2-10%) of YFP-labeled cells could not be identified with a battery of antibodies against neurons, glia, neural stem/progenitor cells, vascular or immune system cells.
We also report that Tam pre-treatment resulted in significantly reduced locomotor disability in female but not male mice with EAE.
All animal work conformed to local ethical committee guidelines and the Animals (Scientific Procedures) Act 1986 and was specifically approved by the UK Government Home Office. Pdgfra-CreERT2 BAC transgenic mice have been described (Rivers et al., 2008).They were made by pronuclear injection of C57Bl6/ CBA F1 hybrids and maintained on the Rosa26R-YFP (R26R-YFP) reporter background (Srinivas et al., 2001). Cre recombination was induced by administering tamoxifen (Tam; Sigma, 40 mg/ml), dissolved in corn oil (Sigma, C8267) by sonication for 45 minutes at 30°C. Adult mice were given 300 mg/Kg body weight by oral gavage on four consecutive days starting 14 days prior to EAE induction (Fig. 1). Our Pdgfra-CreERT2 line expresses Cre exclusively in PDGFRA-immunoreactive precursors (Rivers et al., 2008) but not in differentiated OLs, which do not express PDGFRA (Butt et al., 1997;Hall et al., 1996). Cre-mediated recombination is completely absent in the absence of Tam and continues in the spinal cord for at most ten days following Tam induction (Psachoulia et al., 2009). The efficiency of Cre recombination (proportion of PDGFRA+ cells that became YFP+) in the adult spinal cord was ~30% and this fraction remained stable between 14 and 42 days post-Tam. This was slightly lower than we found previously in the adult forebrain (~45-50%) (Rivers et al., 2008).
EAE was induced in 14-18 week old (postnatal day ~110, ~P110) male and virgin female Pdgfra-CreERT2: R26R-YFP mice by immunizing with emulsified MOG peptide (amino acids 35-55) together with Freund’s adjuvant [1 mg/ml MOG peptide, 2.5 mg/ml Mycobacterium tuberculosis in 50% (v/v) incomplete Freund’s adjuvant, 50% (v/v) phosphate-buffered saline (PBS)], injected subcutaneously on days 0 and 7 (i.e. 14 and 21 days post-Tam). In addition, 0.1 ml Pertussis toxin (300 ng/ml) was injected intra-peritoneally on days 0 and 2. Mock-immunized animals received the same inoculum without MOG peptide. The time line of the experiments is illustrated in Fig. 1A. We analyzed three groups of mice that had received 1) Tam in corn oil followed by mock-EAE immunization (“Tam-only”), 2) corn oil followed by EAE inoculum (“EAE-only”) and 3) Tam followed by EAE inoculum (“Tam+EAE”).
All mice were evaluated daily for signs of locomotor disability on a 7 point scale (supplementary Table S1). Mice showing severe spasticity or a score above 5 were killed immediately by a humane method.
Mice were perfused intra-cardially with 4% (w/v) paraformaldehyde (PFA) in PBS at room temperature (~20°C). Spinal cords were dissected and post-fixed in 4% PFA overnight at 4°C. Tissue was cryo-protected in 20% (w/v) sucrose at 4°C overnight, embedded in OCT compound, frozen and stored at −80°C until sectioning. Spinal cords at the cervical, thoracic and lumbar levels were sectioned at 30 μm nominal thickness and collected by floating on the surface of PBS.
Floating spinal cord sections were pre-treated with blocking solution [10% (v/v) sheep serum, 0.1% (v/v) Triton-X100 in PBS], incubated with primary antibodies overnight at 4°C then secondary antibodies for one hour at 20-25°C. Details of primary antibodies are given in supplementary Table S2. Solochrome Cyanine dye was used to visualize myelin. The following secondary antibodies were used in blocking solution: Alexa Fluor 488 goat anti-rat IgG (Invitrogen, 1:500), Alexa Fluor 567 goat anti-mouse IgG1, Alexa Fluor 647 goat anti-rabbit IgG (Invitrogen, 1:1000) and Cy3-conjugated donkey anti-guinea pig IgG (Chemicon, 1:500). Fluorescein-conjugated isolectin B4 from Bandeiraea (Griffonia) simplicifolia (ILB4, Vector Labs, 1:100) was used to label microglia and endothelial cells. Cell nuclei were visualized by post-staining with Hoescht 33258 (Sigma, 1:1000). Sections were transferred to Superfrost Plus slides and dried in air, mounted in DAKO under coverslips and examined in a Perkin Elmer Ultraview confocal microscope.
Two sections from each level (cervical, thoracic and lumbo-sacral) of the spinal cord were analyzed for every animal. Seven arbitrary non-overlapping sample fields were counted in the white matter and six fields in the gray matter of every section (Fig. 1B) and data were pooled per section, then per animal. Data from white matter (WM) and gray matter (GM) were kept separate. WM and GM boxes were distinct and non-overlapping with an area of 0.11 mm2 (Fig. 1B). However, if a WM box straddled WM and GM - which sometimes happened in lumbo-sacral spinal cord - the cells in GM were easily excluded since GM and WM could be visually distinguished. The general strategy was to place at least one WM box in each of the dorsal, dorso-lateral, lateral and ventral funiculi and to place two GM boxes in each of the dorsal horn, ventral horn and intermediate GM areas. Since, EAE results in multiple diffuse areas of demyelination instead of necessarily sharp delineated lesions, we decided to take this non-selective approach to field selection. Data were plotted and statistical analyses performed using Graph Prism 5.0 software. All data are plotted as mean ± standard error of the mean (s.e.m.).
Our EAE paradigm (Fig. 1) produced locomotor disability beginning in the second week after initial immunization. Our locomotor scoring criteria are shown in supplementary Table S1. A progressive worsening of locomotion was observed following the onset of symptoms (Fig. 2A), with a few (9 out of 32) mice showing a relapsing-remitting phenotype (not evident in Fig. 2A because the data are pooled). Male and female mice (EAE-only) showed similar progression curves (Fig. 2A). There was a tendency for males to show earlier onset of symptoms but this did not reach statistical significance. Since it was necessary to administer Tam to our mice in order to fate-map PDGFRA/ NG2 cells during EAE, we asked whether Tam itself might have an effect on disease progression (Tam+EAE mice). Several Tam+EAE males were very severely affected (5 on the locomotor scale), which was never seen in the control group that received corn oil without Tam (EAE-only males) (Fig. 2B). Moreover, all of the Tam+EAE males had to be humanely killed before 28 days post-EAE immunization because of the severity of their symptoms; this curtailed the experiment before a statistically significant difference between Tam+EAE and EAE-only males was established. Nevertheless, there was a trend towards more severe outcome in Tam+EAE male mice (Fig. 2B). In contrast, Tam treatment decreased the severity of EAE symptoms in Tam+EAE females (Fig. 2C). Neither male nor female Tam-only mice displayed any locomotor disability.
Different EAE induction protocols result in different disease courses and this can be mouse strain-specific. We therefore checked whether immunization with MOG peptide caused demyelination in our Pdgfra-CreERT2: R26R-YFP mice. Myelin histochemistry (with Solochrome cyanine) and myelin basic protein (MBP) immunohistochemistry revealed demyelinated plaques/lesions all along the rostral-caudal extent of the spinal cord (Fig. 3A, B) accompanied by a robust inflammatory response (Fig. 3C, D).
To determine the fates of PDGFRA cells following EAE immunization we examined spinal cord tissue on 14 days post immunization (14 dpi), when most animals had begun to show locomotor symptoms, and also on 28 dpi (females) or 24 dpi (males). No significant differences were noted among these time-points (nor between males and females) by any of our immunolabelling criteria, so data for all time points and both sexes were subsequently pooled.
In Tam+EAE mice there was an ~4.5-fold increase in YFP+ cells in the white matter and an ~2-fold increase in the grey matter of the spinal cord (Fig. 3E, F; Fig. 4I). These are average figures; there was variation among individual mice - from 2- to 7-fold in white matter, for example. Since there were more YFP+ cells in grey matter to begin with, this resulted ultimately in a roughly even distribution of YFP+ cells in the grey and white matter of Tam+EAE animals (Fig. 4I). Most YFP+ cells in Tam+EAE spinal cords were OLIG2+, identifying them as OL lineage cells (92 ± 2% in white matter, 96 ± 2% in grey) (Fig. 4A-C, G). In Tam-only animals 98 ± 1% of YFP+ cells were also OLIG2+ in white matter, compared to 92 ± 1% in grey (Fig. 4G). A large fraction of YFP+ cells was also NG2+, both in Tam+EAE mice (71 ± 5% in white matter, 72 ± 5% in grey) and Tam-only mice (78 ± 2% in white, 80 ± 6% in grey) (Fig. 4D-F, H).
Approximately 2% of all YFP+ cells in the white matter of Tam-only tissue (5/229 cells in 30 sections) and Tam+EAE tissue (18/970) were GFAP+ (Fig. 4J). In grey matter, ~1% (9/898) of YFP+ cells were GFAP+ in Tam+EAE mice, compared to ~0.4% (2/466) in Tam-only animals. Because GFAP is expressed at a low level or not at all in protoplasmic astrocytes in grey matter, we also co-immunolabeled for YFP and S100β, which is expressed by astrocytes and a subset of oligodendrocyte lineage cells. We did not detect YFP+, S100β+ double-labeled cells in TAM+EAE mice, even in or around lesions. It was originally reported that the Rosa promoter has undetectable activity in mature astrocytes (Malatesta et al 2003) but we have found that both fibrous and protoplasmic astrocytes are strongly labelled in P50 Fgfr3-CreERT2: Rosa26-YFP animals (Young et al 2010). Hence the use of the Rosa26-YFP reporter does not preclude our ability to detect astrocytes. Approximately 1.4% (10/716) of YFP+ cells in Tam-only spinal cords were NeuN+ and ~0.2% (4/2147) in Tam+EAE cords (supplementary Fig. S1). A small number of new neurons generated from the SVZ have been previously reported in a subpopulation of multiple sclerosis lesions (Chang et al., 2008). However it is unclear if these were generated from NG2 cells. Taken together, the evidence indicates that PDGFRA/NG2 glia generate very few, if any, astrocytes or neurons in the EAE spinal cord.
In agreement with previous data (Ligon et al., 2006), we did not detect any NG2+ cells that were not also OLIG2+ in Tam+EAE or Tam-only spinal cords (data not shown). Since more YFP+ cells were OLIG2+ than NG2+ (e.g. 92% versus 71%, respectively, in Tam+EAE white matter; Fig. 4G, H), it follows that a subset of OLIG2+ cells (~21% in this example) were NG2-negative, differentiated OLs. The proportion was similar in Tam-only white matter (~20%). Since there were ~4.5 times more YFP+ cells on average in Tam+EAE white matter compared to Tam-only white matter, it is clear that many new differentiated OLs are generated in response to EAE induction.
To look for direct evidence of remyelinating OL production, we double-immunolabeled Tam+EAE spinal cords for YFP and one of the following markers of differentiated/ myelinating oligodendrocytes: adenomatous polyposis coli (APC, recognized by monoclonal CC1), 2′, 3′-cyclic nucleotide phosphodiesterase (CNP), MBP, Tmem10/Opalin or Ermin/Juxtanodin. APC is found in oligodendrocyte cell bodies and proximal processes, CNP and MBP in cell bodies, processes and myelin sheaths. Tmem10/Opalin is expressed at the onset of myelination in the OL cell body, processes and at the internodes (Golan et al., 2008). Ermin/Juxtanodin is an oligodendrocyte cytoskeletal-related protein that is found in the cytoplasmic tongue processes and terminal loops of compact myelin (Zhang et al., 2005;Brockschnieder et al., 2006). Its temporal expression profile closely follows that of MBP. YFP is a large cytoplasmic protein that is physically excluded from compact myelin, so it is difficult to correlate YFP expression with myelin wraps. Nevertheless, we found many YFP+ cell bodies and processes that also co-labeled for CNP (Fig. 5A-C), APC (Fig. 5D-I) or Opalin (Fig. 6C-E). We estimated that in Tam+EAE animals 35% ± 12% of 404 YFP+ cells, and in Tam-only animals, 21% ± 7% of 183 YFP+ cells were also CC1+ (mean ± s.e.m., 30 sections from three mice). Both YFP+/Opalin+ and YFP+/Ermin+ cells could be found in close apposition to Neurofilament-positive profiles (Fig. 6A, B, F-H) but these were not numerous, presumably because YFP is excluded from the myelin sheaths. Consequently, we cannot be certain that the new OLs all form myelin; it is possible that some or many of them are differentiated but not myelin-forming either because of the lack of suitable axons or because the pathological conditions of EAE inhibit myelination. To address this issue we would need a reporter transgene that specifically labels myelin sheaths but such a reporter is not yet available.
In both Tam-only and Tam+EAE spinal cords there was a subset of YFP+ cells that was not accounted for by immunolabelling for NG2, OLIG2, GFAP or NeuN. These unidentified cells were rare in Tam-only white matter (~2% of YFP+ cells) but became more numerous during EAE (~13% of YFP+ cells) (Fig. 4G). In grey matter, ~13% of YFP+ cells in Tam-only mice and ~9% in Tam+EAE mice were unaccounted for (Fig. 4G). This contrasts with our previous study, in which we could co-label essentially all YFP+ cells in the grey and white matter of the normal adult forebrain with antibodies against OLIG2, NG2, or NeuN (Rivers et al., 2008). We considered the possibility that our present study might have failed to detect 100% of OL lineage cells with our OLIG2 antibody for technical reasons. However, we found that the YFP+, OLIG2-negative cells also failed to label for SOX10 in triple-label experiments (see supplementary Fig. S2), arguing against a purely technical problem and suggesting that they might be non-OL lineage cells.
We tried, unsuccessfully, to identify these OLIG2-negative cells with a battery of antibodies against blood-borne cells (T-cells, B-cells, monocytes, macrophages, neutrophils and granulocytes), vascular cells (endothelial cells and pericytes), CNS-resident microglia, neural stem cells, neural progenitor cells, or immature neurons (supplementary Table S2, Fig. S3). A few YFP+ cells could be immunolabeled for the Schwann cell myelin marker Protein zero (P0) but these were rare relative to the OLIG2-negative YFP+ cells (supplementary Fig. S4). Moreover, they were almost always found close to the pial surface whereas most of the OLIG2-negative, YFP+ cells were in the interior of the cord. The YFP+, OLIG2-negative cells therefore remain unidentified.
The main purpose of our study was to investigate the fates of NG2 cells in a demyelinating/ remyelinating disease model, EAE. Using Cre-lox methodology in transgenic mice, we found that there was a significant increase (>4-fold) in the overall number of OL lineage cells (YFP+, OLIG2+) in the demyelinating cord and a parallel ~4-fold increase in the number of differentiated OLs (YFP+, OLIG2+, NG2-negative; Fig. 4G, H). This is an underestimate of the increase that occurs within lesion areas, since our counting method did not discriminate between lesions and adjacent normal-appearing white matter, thus “diluting” the increase within lesions. New YFP+ OLs could be co-immunolabeled with antibody CC1, an accepted OL differentiation marker. The number of YFP+, CC1+ OLs (~35% of YFP+ cells) in Tam+EAE mice (40 days post-Tam) exceeded the number of YFP+, OLIG2+, NG2-negative cells (~20% of all YFP+ cells). This discrepancy might be down to the fact that there is some overlap between NG2 and CC1 expression in newly-differentiating OLs. Nevertheless, there clearly was a lot of OL differentiation from PDGFRA/ NG2 cells in Tam+EAE mice. We presume that the newly-formed OLs are engaged in remyelinating axons that had become demyelinated during the course of EAE. A generally accepted hallmark of remyelinating OLs is that they generate thinner myelin sheaths (less wraps) than developmentally-generated OLs. To detect myelin directly would require electron microscopy (EM), but we have been unable to identify YFP-labeled myelin sheaths unambiguously by EM immunohistochemistry, because YFP is physically excluded from compact myelin (Rivers et al., 2008).
Even in Tam-only spinal cord ~20% of YFP+, OLIG2+ cells in white matter were NG2-negative at 40 days post-Tam and a similar fraction in grey matter, so new OLs are generated in the healthy adult spinal cord. This was confirmed by the fact that ~21% of YFP+ cells co-immunolabeled with antibody CC1 in Tam-only spinal cord. We and others have previously shown that new myelinating OLs are continue to be formed for an extended period after birth (at least eight months) in the forebrain grey and white matter (Dimou et al., 2008;Rivers et al., 2008;Lasiene et al., 2009;Psachoulia et al., 2009).
Apart from remyelinating OLs, many hypertrophic “reactive” astrocytes appear in the demyelinating/ remyelinating spinal cord (supplementary Fig. S3). These GFAP+ astrocytes tend to accumulate at the periphery of demyelinated lesions where they form a dense glial “scar”. This could be a barrier to inward migration of NG2 cells and thus might inhibit repair, especially after multiple episodes of demyelination at the same locus such as occurs in relapsing-remitting MS. The origin of reactive astrocytes has been controversial, some reports suggesting that they are generated from NG2 cells (Alonso, 2005;Tatsumi et al., 2005;Horky et al., 2006;Leoni et al., 2009). However, the data presented here do not support that view, for we found that only small numbers of YFP+, GFAP+ astrocytes were generated from Pdgfra-CreERT2 – expressing cells, either in the normal healthy spinal cord or after EAE induction. This accords with another recent study of cell generation in a mouse model of acute focal demyelination (stereotaxic injection of ethidium bromide or lysolecithin into spinal cords of Pdgfra-CreERT2: R26R-YFP mice) (Zawadzka et al., 2010). The latter study also demonstrated extensive oligodendrocyte regeneration from PDGFRA/ NG2 cells but little reactive astrocyte production. However, Zawadzka et al. (2010) found that reactive astrocytes surrounding gliotoxin-induced lesions were YFP-labeled in Fgfr3-CreERT2: R26R-YFP mice, in which parenchymal astrocytes and ependymal zone (EZ) cells but not PDGFRA/ NG2 cells are labeled (Young et al., 2010). Therefore it is likely that most reactive astrocytes in and around areas of demyelination are formed by activation and migration of EZ stem cells and/or by multiplication of pre-existing parenchymal astrocytes. Further fate mapping experiments with astrocyte- and EZ-specific Cre lines would be required to distinguish these possibilities.
The lack of significant astrocyte production from PDGFRA/ NG2 glia in our current study and that of Zawadzka et al. (2010) seems at odds with previous reports (Alonso, 2005;Magnus et al., 2007;Sellers et al., 2009;Zhao et al., 2009). However, all of the latter studies involved stab or cut injury models, not demyelination. The fates of stem/precursor cells will be influenced by the local environment near the injury site and this is likely to depend on the nature of the insult. It is possible that we might have underestimated astrocyte production specifically within lesions, for the same reason that we underestimated OL production (the “dilution” effect of our counting method, described above). However, note that the study of Zawadzka et al. (2010) did not suffer from this dilution effect because they counted cells specifically within focal lesions. Another potential source of disparity between our study and others who reported astrocyte production from NG2 cells is in the experimental approach or its interpretation. Some previous studies have relied on co-expression of antigens to infer lineage relationships and have concluded, on the basis of co-expression of NG2 and GFAP, that NG2 glia start to express GFAP on their way to generating astrocytes. However, it also seems possible that GFAP+ astrocytes start to express NG2 and/or OLIG2, perhaps as part of a de-differentiation program, before going on to generate more astrocytes.
In our own study, only ~30% of PDGFRA+ cells in the spinal cords of Pdgfra-CreERT2: R26R-YFP mice recombined and expressed YFP. It is therefore conceivable that the recombined cells are not representative of the population as a whole and that the low level of astrocyte production is an artifact of this selectivity. We have tried to discover whether Cre recombination marks a particular sub-group of OLPs. For example, in the forebrain there are distinct subsets of adult OLPs that are 1) mitotically active or quiescent and 2) developmentally derived from ventral or dorsal neuroepithelium. We have shown that the OLPs that undergo Cre recombination are equally likely to fall into any of these subgroups (Rivers et al., 2008; Psachoulia et al., 2009). We therefore think it likely that the lack of complete recombination in our experiments is simply a function of the relatively low activity of CreERT2 (compared to constitutive Cre), the narrow window of opportunity for recombination following Tamoxifen treatment and possibly a low level of Cre transcription from the Pdgfra promoter (discussed in Young et al., 2010). Inefficient cell labelling is not unusual with CreER lines (e.g. Dimou et al., 2008; Guo et al., 2009).
Unexpectedly, we found a significant minority (2-10%) of YFP+ cells in the spinal cords of healthy as well as EAE mice that did not co-label with antibodies against OLIG2, SOX10 or NG2. These cells therefore seem not to belong to the OL lineage. They also did not label with any of a battery of reagents selected to identify resident or infiltrating immune system cells (microglia, macrophages, neutrophils, T- or B-lymphocytes), vascular mural cells (endothelial cells or pericytes), astrocytes or neurons. Each of these cell types could be detected in the EAE spinal cord but none was YFP+. We also failed to label any YFP+ cells for markers of immature neural precursor/ stem cells. Rare YFP+ Schwann cells were detected but these could not account for the majority of “mystery” cells. Therefore, the YFP+ non-OL lineage cells remain unidentified. Given the presence of some of these mystery cells in healthy mice that received Tam but no EAE inoculum, we presume that they are a normal cell type of the mouse spinal cord. We did not previously detect any such cells in the adult mouse forebrain so they seem to be CNS region-specific.
An unexpected finding was that Tam administration reduced locomotor deficits in female mice with EAE, even though the first EAE inoculum was administered ten days after the final dose of Tam. Perhaps Tam produces a long-lasting effect on the immune system that moderates subsequent autoimmune attack. Alternatively, a low level of Tam might still have been present in our mice at the time of EAE induction and during the course of the disease. Acute Tam treatment is known to be protective during experimental ischemia or stroke (Kimelberg et al., 2000;Kimelberg et al., 2003;Zhang et al., 2007). This protection is due to an anti-oxidant effect of Tam treatment, not binding of Tam to estrogen receptors, and is evident at a very low dose of Tam compared to that used in our current study (a single dose of 5 mg/Kg body weight, versus four doses of 300 mg/Kg) (Zhang et al., 2007). Low dose Tam (5 mg/Kg) has recently been reported to be beneficial following a spinal cord contusion injury in male rats (Tian et al., 2009). The beneficial effect noted in our EAE study was restricted to female mice; in males Tam appeared to have a damaging effect, advancing the onset of locomotor deficits and accelerating subsequent deterioration. Therefore, the action of Tam is likely to be complex, including both short and long term effects and mediated via estrogen receptors as well as other routes.
In conclusion, we have shown that in a MOG-induced EAE model of demyelinating disease, PDGFRA/ NG2 cells in the adult mouse spinal cord generate elevated numbers of OL lineage cells, including differentiated - presumably remyelinating - OLs, but very few astrocytes or neurons.
We thank Ulla Dennehy for technical assistance. We are grateful to Ori Peles, Michael Wegner, Marcus Fruttiger and Clare Isacke for providing antibodies. L.E.R. was supported by a collaborative studentship from the Biotechnology and Biological Sciences Research Council and Eisai London Research Laboratories at University College London. F.J. was supported by a Marie Curie Fellowship from the European Union. K.Y is supported by Alzheimer’s Society Collaborative Career Award. The work was also funded by grants to W.D.R. from the Medical Research Council and The Wellcome Trust.